Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A cancer and leukemia group B study

✍ Scribed by Jeffrey J. Kirshner; James R. Anderson; Barbara Parker; Maurice Barcos; M. Robert Cooper; Linda J. Burns; Bruce A. Peterson; Arlan J. Gottlieb

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 468 KB
• Volume: 71
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19930301)71:5<1852::aid-cncr2820710523>3.0.co;2-t

✦ Synopsis

Background. In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease.

Thirty-six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophosphamide (MOPLEC), and then treated with five to seven additional courses of a known "curative" regimen: nitrogen mustard, vinblastine, prednisone, and procarbazine (MVPP).

After treatment with MOPLEC, there were 16 complete responders (44%) and 18 partial responders (50%). One patient had progressive disease and one patient was taken off study after an anaphylactic reaction to etoposide. After completing the entire protocol, 32 patients achieved complete remission (CR) (89%) and 3 achieved partial remission (PR) (8"/0). Five CR patients have relapsed and three additional patients have died in CR without recurrence. At 36 months, the estimated failure-free survival is 61% and overall survival is 72%.

Methods.

Results.